Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zansecimab (LY3127804) in hospitalized COVID-19 pneumonia
NCT04342897Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2020
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zansecimab in COVID-19 pneumonia, sponsored by Eli Lilly and Company. Started Apr 2020; status: terminated.
02
Drugs
zansecimab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04342897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04342897.